James, in the targeted NAL condition subjects were instructed to take NAL 1-2 hours before a high risk drinking situation. The authors stated that, I could not find their explanation for why they thought this to be likely. They don't mention TSM, they don't reference Sinclair but they seem to be applying TSM to this study design. A possible explanation of why targeted was more effective than daily may be receptor upregulation and alcohol deprivation effect but this is purely speculative.

I'll look up Sinclair's score later. I do have access to a major university health science library so I should be able to find it.

I'll try to PM you a PDF of the study. I would rather not post it here since it may be considered a copyright infringement since it is not free access yet.

I can find no citations in the medical literature for Eskapa
Sinclair has quite a lot - my quick survey suggests he has a h-index of 23, which I guess is reasonable for someone in the medical field (where citation tends to be very high)

His 'main' paper, i.e. "Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: A factorial double-blind, placebo-controlled trial
" (2001 Journal of Clinical Psychopharmacology 21 (3), pp. 287-292) has been cited 102 times

FWIW, here they are:

References

Garbutt, J. C. (2010). Efficacy and tolerability of naltrexone in the management of alcohol dependence. Current Pharmaceutical Design, 16(19), 2091-2097. Retrieved from www.scopus.com
Foa, E. B., & Williams, M. T. (2010). Methodology of a randomized double-blind clinical trial for comorbid posttraumatic stress disorder and alcohol dependence. Mental Health and Substance use: Dual Diagnosis, 3(2), 131-147. Retrieved from www.scopus.com
Ray, L. A., Chin, P. F., & Miotto, K. (2010). Naltrexone for the treatment of alcoholism: Clinical findings, mechanisms of action, and pharmacogenetics. CNS and Neurological Disorders - Drug Targets, 9(1), 13-22. Retrieved from www.scopus.com
Chatterjee, S., & Bartlett, S. E. (2010). Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders. CNS and Neurological Disorders - Drug Targets, 9(1), 60-76. Retrieved from www.scopus.com
Greenfield, S. F., Shields, A., Connery, H. S., Livchits, V., Yanov, S. A., Lastimoso, C. S., et al. (2010). Integrated management of physician-delivered alcohol care for tuberculosis patients: Design and implementation. Alcoholism: Clinical and Experimental Research, 34(2), 317-330. Retrieved from www.scopus.com
Brown, E. S., Carmody, T. J., Schmitz, J. M., Caetano, R., Adinoff, B., Swann, A. C., et al. (2009). A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. Alcoholism: Clinical and Experimental Research, 33(11), 1863-1869. Retrieved from www.scopus.com
Magill, M., & Ray, L. A. (2009). Cognitive-behavioral treatment with adult alcohol and illicit drug users: A meta-analysis of randomized controlled trials. Journal of Studies on Alcohol and Drugs, 70(4), 516-527. Retrieved from www.scopus.com
Kranzler, H. R., Tennen, H., Armeli, S., Chan, G., Covault, J., Arias, A., et al. (2009). Targeted naltrexone for problem drinkers. Journal of Clinical Psychopharmacology, 29(4), 350-357. Retrieved from www.scopus.com
Czachowski, C. L., & Delory, M. J. (2009). Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats. Psychopharmacology, 204(2), 335-348. Retrieved from www.scopus.com
Morley, K. C., Teesson, M., Sannibale, C., & Haber, P. S. (2009). Sample bias from different recruitment strategies in a randomised controlled trial for alcohol dependence. Drug and Alcohol Review, 28(3), 222-229. Retrieved from www.scopus.com
Mitchell, J. M., Bergren, L. J., Chen, K. S., Rowbotham, M. C., & Fields, H. L. (2009). Naltrexone aversion and treatment efficacy are greatest in humans and rats that actively consume high levels of alcohol. Neurobiology of Disease, 33(1), 72-80. Retrieved from www.scopus.com
Williams, K. L., & Schimmel, J. S. (2008). Effect of naltrexone during extinction of alcohol-reinforced responding and during repeated cue-conditioned reinstatement sessions in a cue exposure style treatment. Alcohol, 42(7), 553-563. Retrieved from www.scopus.com
Muhonen, L. H., Lahti, J., Sinclair, D., Lönnqvist, J., & Alho, H. (2008). Treatment of alcohol dependence in patients with co-morbid major depressive disorder - predictors for the outcomes with memantine and escitalopram medication. Substance Abuse: Treatment, Prevention, and Policy, 3 Retrieved from www.scopus.com
Juárez, J., & De Tomasi, E. B. (2008). Naltrexone treatment produces dose-related effects on food and water intake but daily alcohol consumption is not affected. Nutritional Neuroscience, 11(4), 183-192. Retrieved from www.scopus.com
Roth-Deri, I., Green-Sadan, T., & Yadid, G. (2008). β-Endorphin and drug-induced reward and reinforcement. Progress in Neurobiology, 86(1), 1-21. Retrieved from www.scopus.com
Leeman, R. F., Palmer, R. S., Corbin, W. R., Romano, D. M., Meandzija, B., & O'Malley, S. S. (2008). A pilot study of naltrexone and BASICS for heavy drinking young adults. Addictive Behaviors, 33(8), 1048-1054. Retrieved from www.scopus.com
Oslin, D. W., Lynch, K. G., Pettinati, H. M., Kampman, K. M., Gariti, P., Gelfand, L., et al. (2008). A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcoholism: Clinical and Experimental Research, 32(7), 1299-1308. Retrieved from www.scopus.com
Ray, L. A., Hutchison, K. E., MacKillop, J., Miranda Jr., R., Audette, A., Swift, R., et al. (2008). Effects of naltrexone during the descending limb of the blood alcohol curve. American Journal on Addictions, 17(4), 257-264. Retrieved from www.scopus.com
Snyder, J. L., & Bowers, T. G. (2008). The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: A relative benefits analysis of randomized controlled trials. American Journal of Drug and Alcohol Abuse, 34(4), 449-461. Retrieved from www.scopus.com
Perney, P., Rigole, H., & Blanc, F. (2008). Alcohol dependence: Diagnosis and treatment. [Alcoolodépendance : diagnostic et traitement] Revue De Medecine Interne, 29(4), 297-304. Retrieved from www.scopus.com
Soyka, M., Kranzler, H. R., Berglund, M., Gorelick, D., Hesselbrock, V., Johnson, B. A., et al. (2008). World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism. World Journal of Biological Psychiatry, 9(1), 6-23. Retrieved from www.scopus.com
Laaksonen, E., Koski-Jännes, A., Salaspuro, M., Ahtinen, H., & Alho, H. (2008). A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol and Alcoholism, 43(1), 53-61. Retrieved from www.scopus.com
Rösner, S., Leucht, S., Lehert, P., & Soyka, M. (2008). Acamprosate supports abstinence, naltrexone prevents excessive drinking: Evidence from a meta-analysis with unreported outcomes. Journal of Psychopharmacology, 22(1), 11-23. Retrieved from www.scopus.com
Mason, B. J., & Crean, R. (2007). Acamprosate in the treatment of alcohol dependence: Clinical and economic considerations. Expert Review of Neurotherapeutics, 7(11), 1465-1477. Retrieved from www.scopus.com
Ray, L. A., & Hutchison, K. E. (2007). Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: A double-blind placebo-controlled study. Archives of General Psychiatry, 64(9), 1069-1077. Retrieved from www.scopus.com
Roozen, H. G., De Waart, R., & Van Den Brink, W. (2007). Efficacy and tolerability of naltrexone in the treatment of alcohol dependence: Oral versus injectable delivery. European Addiction Research, 13(4), 201-206. Retrieved from www.scopus.com
Davidson, D., Wirtz, P. W., Gulliver, S. B., & Longabaugh, R. (2007). Naltrexone's suppressant effects on drinking are limited to the first 3 months of treatment. Psychopharmacology, 194(1), 1-10. Retrieved from www.scopus.com
Karhuvaara, S., Simojoki, K., Virta, A., Rosberg, M., Löyttyniemi, E., Nurminen, T., et al. (2007). Targeted nalmefene with simple medical management in the treatment of heavy drinkers: A randomized double-blind placebo-controlled multicenter study. Alcoholism: Clinical and Experimental Research, 31(7), 1179-1187. Retrieved from www.scopus.com
Batki, S. L., Dimmock, J. A., Wade, M., Gately, P. W., Cornell, M., Maisto, S. A., et al. (2007). Monitored naltrexone without counseling for alcohol abuse/dependence in schizophrenia-spectrum disorders. American Journal on Addictions, 16(4), 253-259. Retrieved from www.scopus.com
Gueorguieva, R., Wu, R., Pittman, B., Cramer, J., Rosenheck, R. A., O'Malley, S. S., et al. (2007). New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biological Psychiatry, 61(11), 1290-1295. Retrieved from www.scopus.com
Part A: Treatment recommendations for patients with substance use disorders.(2007). American Journal of Psychiatry, 164(4 SUPPL.), 5-123. Retrieved from www.scopus.com
Tambour, S., & Quertemont, E. (2007). Preclinical and clinical pharmacology of alcohol dependence. Fundamental and Clinical Pharmacology, 21(1), 9-28. Retrieved from www.scopus.com
Juárez, J., & Eliana, B. D. T. (2007). Alcohol consumption is enhanced after naltrexone treatment. Alcoholism: Clinical and Experimental Research, 31(2), 260-264. Retrieved from www.scopus.com
Mitchell, J. M., Tavares, V. C., Fields, H. L., D'Esposito, M., & Boettiger, C. A. (2007). Endogenous opioid blockade and impulsive responding in alcoholics and healthy controls. Neuropsychopharmacology, 32(2), 439-449. Retrieved from www.scopus.com
Diehl, A., & Mann, K. (2007). Pharmacological relapse prevention in alcohol and tobacco dependence. [Pharmakologische rückfallprävention bei alkohol- und tabakabhängigkeit] Internist, 48(1), 79-88. Retrieved from www.scopus.com
Angelini, M., & Brahmbhatt, Y. (2007). A review of the pharmacologic options for the treatment of alcohol dependence. Formulary, 42(1), 14-31. Retrieved from www.scopus.com
Soyka, M., & Roesner, S. (2006). New pharmacological approaches for the treatment of alcoholism. Expert Opinion on Pharmacotherapy, 7(17), 2341-2353. Retrieved from www.scopus.com
Weiss, R. D., & Kueppenbender, K. D. (2006). Combining psychosocial treatment with pharmacotherapy for alcohol dependence. Journal of Clinical Psychopharmacology, 26(6 SUPPL. 1), S37-S42. Retrieved from www.scopus.com
Pettinati, H. M., O'Brien, C. P., Rabinowitz, A. R., Wortman, S. P., Oslin, D. W., Kampman, K. M., et al. (2006). The status of naltrexone in the treatment of alcohol dependence: Specific effects on heavy drinking. Journal of Clinical Psychopharmacology, 26(6), 610-625. Retrieved from www.scopus.com
Petrakis, I. L. (2006). A rational approach to the pharmacotherapy of alcohol dependence. Journal of Clinical Psychopharmacology, 26(6 SUPPL. 1), S3-S12. Retrieved from www.scopus.com
Paidisetty, S., & Gordon, A. J. (2006). Pharmacologic management of alcohol use disorders in the primary care setting. Journal of Clinical Outcomes Management, 13(11), 628-646. Retrieved from www.scopus.com
Petrakis, I. L., Nich, C., & Ralevski, E. (2006). Psychotic spectrum disorders and alcohol abuse: A review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophrenia Bulletin, 32(4), 644-654. Retrieved from www.scopus.com
Green, A. I. (2006). Treatment of schizophrenia and comorbid substance abuse: Pharmacologic approaches. Journal of Clinical Psychiatry, 67(SUPPL. 7), 31-35. Retrieved from www.scopus.com
Ait-Daoud, N., Malcolm Jr., R. J., & Johnson, B. A. (2006). An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants. Addictive Behaviors, 31(9), 1628-1649. Retrieved from www.scopus.com
Roozen, H. G., de Waart, R., van der Windt, D. A. W. M., van den Brink, W., de Jong, C. A. J., & Kerkhof, A. J. F. M. (2006). A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. European Neuropsychopharmacology, 16(5), 311-323. Retrieved from www.scopus.com
Cowen, M. S., & Lawrence, A. J. (2006). Alcoholism and neuropeptides: An update. CNS and Neurological Disorders - Drug Targets, 5(2), 233-239. Retrieved from www.scopus.com
Kiefer, F., & Mann, K. (2005). New achievements and pharmacotherapeutic approaches in the treatment of alcohol dependence. European Journal of Pharmacology, 526(1-3), 163-171. Retrieved from www.scopus.com
Deas, D., May, K., Randall, C., Johnson, N., & Anton, R. (2005). Naltrexone treatment of adolescent alcoholics: An open-label pilot study. Journal of Child and Adolescent Psychopharmacology, 15(5), 723-728. Retrieved from www.scopus.com
Carroll, K. M. (2005). Recent advances in the psychotherapy of addictive disorders. Current Psychiatry Reports, 7(5), 329-336. Retrieved from www.scopus.com
Modesto-Lowe, V., & Fritz, E. M. (2005). The opioidergic-alcohol link: Implications for treatment. CNS Drugs, 19(8), 693-707. Retrieved from www.scopus.com
Huang, M. -., Chen, C. -., Yu, J. -., & Chen, C. -. (2005). A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence in taiwan. Addiction Biology, 10(3), 289-292. Retrieved from www.scopus.com
Gastfriend, D. R., Donovan, D., Lefebvre, R., & Murray, K. T. (2005). Developing a baseline assessment battery: Balancing patient time burden with essential clinical and research monitoring. Journal of Studies on Alcohol, 66(SUPPL. 15), 94-103. Retrieved from www.scopus.com
Anton, R. F., Moak, D. H., Latham, P., Waid, L. R., Myrick, H., Voronin, K., et al. (2005). Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. Journal of Clinical Psychopharmacology, 25(4), 349-357. Retrieved from www.scopus.com
Mattson, M. E., & Litten, R. Z. (2005). Combining treatments for alcoholism: Why and how? Journal of Studies on Alcohol, 66(SUPPL. 15), 8-16. Retrieved from www.scopus.com
Mason, B. J. (2005). Rationale for combining acamprosate and naltrexone for treating alcohol dependence. Journal of Studies on Alcohol, 66(SUPPL. 15), 148-156. Retrieved from www.scopus.com
Pelc, I., Hanak, C., Baert, I., Houtain, C., Lehert, P., Landron, F., et al. (2005). Effect of community nurse follow-up when treating alcohol dependence with acamprosate. Alcohol and Alcoholism, 40(4), 302-307. Retrieved from www.scopus.com
Berglund, M. (2005). A better widget? three lessons for improving addiction treatment from a meta-analytical study. Addiction, 100(6), 742-750. Retrieved from www.scopus.com
Feinn, R., & Kranzler, H. R. (2005). Does effect size in naltrexone trials for alcohol dependence differ for single-site vs. multi-center studies? Alcoholism: Clinical and Experimental Research, 29(6), 983-988. Retrieved from www.scopus.com
Srisurapanont, M., & Jarusuraisin, N. (2005). Naltrexone for the treatment of alcoholism: A meta-analysis of randomized controlled trials. International Journal of Neuropsychopharmacology, 8(2), 267-280. Retrieved from www.scopus.com
Petrakis, I. L., Poling, J., Levinson, C., Nich, C., Carroll, K., & Rounsaville, B. (2005). Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biological Psychiatry, 57(10), 1128-1137. Retrieved from www.scopus.com
Litten, R. Z., Fertig, J., Mattson, M. E., & Egli, M. (2005). Development of medications for alcohol use disorders: Recent advances and ongoing challenges. Expert Opinion on Emerging Drugs, 10(2), 323-343. Retrieved from www.scopus.com
Ooteman, W., Verheul, R., Naassila, M., Daoust, M., Schippers, G. M., Koeter, M. W. J., et al. (2005). Patient-treatment matching with anti-craving medications in alcohol-dependent patients: A review on phenotypic, endophenotypic and genetic indicators. Journal of Substance use, 10(2-3), 75-96. Retrieved from www.scopus.com
Breese, G. R., Overstreet, D. H., & Knapp, D. J. (2005). Conceptual framework for the etiology of alcoholism: A "kindling" /stress hypothesis. Psychopharmacology, 178(4), 367-380. Retrieved from www.scopus.com
Saitz, R. (2005). Unhealthy alcohol use. New England Journal of Medicine, 352(6), 596-607. Retrieved from www.scopus.com
Room, R., Babor, T., & Rehm, J. (2005). Alcohol and public health. Lancet, 365(9458), 519-530. Retrieved from www.scopus.com
Banzato, C. E. M., Loper, A. D., & De Azevedo, R. C. S. (2004). Naltrexone in alcohol dependence: Open clinical trial. [Naltrexona na dependência de álcool: Ensaio clínico aberto] Jornal Brasileiro De Psiquiatria, 53(2), 134-138. Retrieved from www.scopus.com
Killeen, T. K., Brady, K. T., Gold, P. B., Simpson, K. N., Faldowski, R. A., Tyson, C., et al. (2004). Effectiveness of naltrexone in a community treatment program. Alcoholism: Clinical and Experimental Research, 28(11), 1710-1717. Retrieved from www.scopus.com
Johnson, B. A. (2004). An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence. Expert Opinion on Pharmacotherapy, 5(9), 1943-1955. Retrieved from www.scopus.com
Lingford-Hughes, A. R., Welch, S., & Nutt, D. J. (2004). Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: Recommendations from the british association for psychopharmacology. Journal of Psychopharmacology, 18(3), 293-335. Retrieved from www.scopus.com
Carroll, K. M., Kosten, T. R., & Rounsaville, B. J. (2004). Choosing a behavioral therapy platform for pharmacotherapy of substance users. Drug and Alcohol Dependence, 75(2), 123-134. Retrieved from www.scopus.com
Švestka, J. (2004). Naltrexone in the treatment of alcohol dependence. [Naltrexon v léčbě závislosti na alkoholu] Psychiatrie, 8(2), 109-116. Retrieved from www.scopus.com
Rohsenow, D. J. (2004). What place does naltrexone have in the treatment of alcoholism? CNS Drugs, 18(9), 547-560. Retrieved from www.scopus.com
Anton, R. F., Pettinati, H., Zweben, A., Kranzler, H. R., Johnson, B., Bohn, M. J., et al. (2004). A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. Journal of Clinical Psychopharmacology, 24(4), 421-428. Retrieved from www.scopus.com
Mann, K. (2004). Pharmacotherapy of alcohol dependence: A review of the clinical data. CNS Drugs, 18(8), 485-504. Retrieved from www.scopus.com
Schmitz, J. M., Stotts, A. L., Sayre, S. L., DeLaune, K. A., & Grabowski, J. (2004). Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy. American Journal on Addictions, 13(4), 333-341. Retrieved from www.scopus.com
Carmen, B., Angeles, M., Ana, M., & María, A. J. (2004). Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction, 99(7), 811-828. Retrieved from www.scopus.com
Dawes, M. A., & Johnson, B. A. (2004). Pharmacotherapeutic trials in adolescent alcohol use disorders: Opportunities and challenges. Alcohol and Alcoholism, 39(3), 166-177. Retrieved from www.scopus.com
Anton, R. F., Drobes, D. J., Voronin, K., Durazo-Avizu, R., & Moak, D. (2004). Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: Temporal effects of drinking. Psychopharmacology, 173(1), 32-40. Retrieved from www.scopus.com
Kranzler, H. R., Armeli, S., Feinn, R., & Tennen, H. (2004). Targeted naltrexone treatment moderates the relations between mood and drinking behavior among problem drinkers. Journal of Consulting and Clinical Psychology, 72(2), 317-327. Retrieved from www.scopus.com
Cowen, M. S., Chen, F., & Lawrence, A. J. (2004). Neuropeptides: Implications for alcoholism. Journal of Neurochemistry, 89(2), 273-285. Retrieved from www.scopus.com
Oswald, L. M., & Wand, G. S. (2004). Opioids and alcoholism. Physiology and Behavior, 81(2), 339-358. Retrieved from www.scopus.com
Vaughn, M. G., & Howard, M. O. (2004). Integrated psychosocial and opioid-antagonist treatment for alcohol dependence: A systematic review of controlled evaluations. Social Work Research, 28(1), 41-55. Retrieved from www.scopus.com
Kiefer, F., Jahn, H., Holzbach, R., Briken, P., Stracke, R., & Wiedemann, K. (2003). The NALCAM-study: Efficacy, tolerability, outcome. [Die NALCAM-studie: Wirksamkeit, verträglichkeit, outcome] Sucht, 49(6), 342-351. Retrieved from www.scopus.com
Mason, B. J. (2003). Acamprosate and naltrexone treatment for alcohol dependence: An evidence-based risk-benefits assessment. European Neuropsychopharmacology, 13(6), 469-475. Retrieved from www.scopus.com
Berglund, M., Thelander, S., Salaspuro, M., Franck, J., Andréasson, S., & Öjehagen, A. (2003). Treatment of alcohol abuse: An evidence-based review. Alcoholism: Clinical and Experimental Research, 27(10), 1645-1656. Retrieved from www.scopus.com
Mark, T. L., Kranzler, H. R., & Song, X. (2003). Understanding US addiction physicians' low rate of naltrexone prescription. Drug and Alcohol Dependence, 71(3), 219-228. Retrieved from www.scopus.com
O'Malley, S. S., Rounsaville, B. J., Farren, C., Namkoong, K., Wu, R., Robinson, J., et al. (2003). Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: A nested sequence of 3 randomized trials. Archives of Internal Medicine, 163(14), 1695-1704. Retrieved from www.scopus.com
Balldin, J., Berglund, M., Borg, S., Månsson, M., Bendtsen, P., Franck, J., et al. (2003). A 6-month controlled naltrexone study: Combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcoholism: Clinical and Experimental Research, 27(7), 1142-1149. Retrieved from www.scopus.com
Gastfriend, D. R. (2003). Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: Rationale and methods. Alcoholism: Clinical and Experimental Research, 27(7), 1107-1122. Retrieved from www.scopus.com
Friedlander, A. H., Marder, S. R., Pisegna, J. R., & Yagiela, J. A. (2003). Alcohol abuse and dependence: Psychopathology, medical management and dental implications. Journal of the American Dental Association, 134(6), 731-740+742. Retrieved from www.scopus.com
Bentley, K. W. (2003). β-Phenylethylamines and the isoquinoline alkaloids. Natural Product Reports, 20(3), 342-365. Retrieved from www.scopus.com
Kranzler, H. R., Armeli, S., Tennen, H., Blomqvist, O., Oncken, C., Petry, N., et al. (2003). Targeted naltrexone for early problem drinkers. Journal of Clinical Psychopharmacology, 23(3), 294-304. Retrieved from www.scopus.com
Anton, R. F., & Swift, R. M. (2003). Current pharmacotherapies of alcoholism: A U.S. perspective. American Journal on Addictions, 12(SUPPL. 1), S53-S68. Retrieved from www.scopus.com
Soyka, M., & Chick, J. (2003). Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: A european perspective. American Journal on Addictions, 12(SUPPL. 1), S69-S80. Retrieved from www.scopus.com
McAlister, F. A., Straus, S. E., Sackett, D. L., & Altman, D. G. (2003). Analysis and reporting of factorial trials: A systematic review. Journal of the American Medical Association, 289(19), 2545-2553. Retrieved from www.scopus.com
Mark, T. L., Kranzler, H. R., Song, X., Bransberger, P., Poole, V. H., & Crosse, S. (2003). Physicians' opinions about medications to treat alcoholism. Addiction, 98(5), 617-626. Retrieved from www.scopus.com
Kiefer, F., Jahn, H., Tarnaske, T., Helwig, H., Briken, P., Holzbach, R., et al. (2003). Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: A double-blind, placebo-controlled study. Archives of General Psychiatry, 60(1), 92-99. Retrieved from www.scopus.com
Gastpar, M., Bonnet, U., Böning, J., Mann, K., Schmidt, L. G., Soyka, M., et al. (2002). Lack of efficacy of naltrexone in the prevention of alcohol relapse: Results from a german multicenter study. Journal of Clinical Psychopharmacology, 22(6), 592-598. Retrieved from www.scopus.com
Bodnar, R. J., & Hadjimarkou, M. M. (2002). Endogenous opiates and behavior: 2001. Peptides, 23(12), 2307-2365. Retrieved from www.scopus.com
Saunders, J. B., & Brady, K. T. (2002). The scientific basis for the prevention and treatment of substance misuse. Current Opinion in Psychiatry, 15(3), 231-234. Retrieved from www.scopus.com
Schmidt, L. G. (2002). Advances in the treatment of alcohol dependence. Current Opinion in Psychiatry, 15(3), 255-260. Retrieved from www.scopus.com
Fuller, R. K., & Gordis, E. (2001). Naltrexone treatment for alcohol dependence. New England Journal of Medicine, 345(24), 1770-1771. Retrieved from www.scopus.com

hmmmmm

one of Sinclairs references is a letter to the New England Journal of Medicine, which is co-signed by a Dr. Marc Shinderman of Illinois. I just did a quick search on the latter to see if he had any publications supporting TSM. An interesting result to say the least!

Shinderman appears to have several felony convictions in different states
http://www.healthgrades.com/directory_s ... ound-check

Now I don't want to damn Sinclair by association, and admittedly the above felonies occur some 5 years after the letter to the NEJM, but it still gave me pause for thought. Some details of the cases are posted here:
http://nama-president.blogspot.com/2006 ... chive.html
which admittedly makes it sound more benign than might be imagined at first.

Yeah seems pretty minor- probably common practice, just never exposed

.

DOMD
I agree, but most folk come in here in the depths of alcoholism and what they are most looking for is support and a bit of hope having heard of tsm. James knocked tsm from get go even though he claimed to be on board, and he even claimed to see benifits from it!?

Yes I agree we have to ask questions but at the end of the day this is a support site for people on the sinclair method. There are more people here that just want to come and log their progress and gain a bit of insight from others that have been here for a few weeks than there are people who want to know the exact science behind it.

Personally I have read everything I could find about TSM but not everybody wants to do that.Right now Im thinking of someone who Ive indroduced to the site. TSM works no matter whether you want to know how it does it or not.

I would love to start a thread here about how much tsm has helped people EVEN if they believe they have NOT beencured. Has it helped? Are they drinking less

.

DOMD, the thing is, nobody ever said he shouldn't question. never. He was just such an ass about it, and he made insulting statements and condescended. He didn't just say "there's not enough evidence" he said "there;s no proff that TSM works...none" no way he was doing TSM! the guy was just some troll. I think there should be more studies too. I'm all for putting the screws to these guys and getting whatever information there is. Tonight I asked Eskapa to post the updated database on clinical studies in humans he promised in the "Dr. sinclair's response to JamesCT" thread. (that's not really the name of the thread) but it's in the general discussion if you haven't seen it.

he ran off goodman too. i, like mario was also thinking about people i've pointed to this site. In fact, in the last 4 days, I've had 2 people interested and asking me about it. I didn't give either one a link here like i normally would've. sad. not saying we shouldn't question, but why come here and constantly attack? I think he ran off goodman too! I hope he's ok

If I went to an AA forum and did nothing but attack AA and say that AA doesn't work, I would understand being met with a chilly response, even banned. but no, he wasn't banned. he was even encouraged to question. and when Eskapa confronted him on it he turned tail and ran like a good little troll.

glad you're still doing well DOMD. lets keep looking for more evidence, keep questioning.

meanwhile I say we let this troll's thread die a natural death. there is a good thread by eskapa in general discussion about proof and studies. a good place where we can question and look for answers. the thread in which the troll signed off before Eskapa posted the follow up database he promised James didn't want answers.

don't post here unless you want to revive a devisive, lamo thread.

Where did this guy go?

MWO forums, "37 degrees" is his name over there.